MANILA, Philippines — The Food and Drug Administration (FDA) has granted a compassionate special permit (CSP) to two physicians for the use of Leronlimab to treat COVID-19 patients.
“Recently, the FDA granted Compassionate Special Permits for Leronlimab as requested by medical specialists for the treatment of COVID-19 patients,” the FDA said in a statement over the weekend.
Leronlimab is an investigational product still undergoing clinical trials for the treatment of cancer and human immunodeficiency virus.
It is also being investigated for use in COVID-19 treatment.
In a text message to INQUIRER.net on Monday, FDA Director Gener…
Keep on reading: FDA grants 2 doctors compassionate special permit to use Leronlimab vs COVID-19